title: Treatment of T1b glottic SCC: laser vs. radiation--a Canadian multicenter study.
abstract: OBJECTIVE
  To assess the oncological and functional outcomes of T1b squamous cell carcinoma (SCC) of the glottic larynx treated with laser in comparison with radiation.
  
  
  METHODS
  A Canadian multicenter cohort study.
  
  
  METHODS
  Three tertiary referral centers for head and neck cancer- Dalhousie University in Halifax, Nova Scotia, Western University in London, Ontario and the University of Manitoba, Winnipeg.
  
  
  METHODS
  Patients with T1b glottic SCC who underwent transoral laser resection or radiation as the primary modality of treatment.
  
  
  METHODS
  Oncological outcomes were evaluated using local control, laryngeal preservation, disease free survival and disease specific survival. Voice outcomes were assessed using the Voice Handicap Index-10 (VHI-10).
  
  
  RESULTS
  63 patients met study criteria. 21 were treated with laser and 42 with radiation. Oncologic outcomes at 2 years for laser and radiation demonstrated local control of 95% and 85.9%; laryngeal preservation of 100% and 85.9%; disease free survival of 88.7% and 85.9% and overall survival of 94.1% and 94.8% respectively. VHI-10 data was available for 23/63 patients. During the last follow up visit VHI-10 ranged from 0 to 11 (median 6) in the laser group and 0 to 34 (median 7) in the radiation group.
  
  
  CONCLUSIONS
  T1b SCC of the glottis can be effectively treated with transoral laser microsurgery with oncological outcomes that are at least equivalent to radiation. For patients with VHI scores, voice quality was similar between the two groups. To our knowledge this is the first study directly comparing the oncologic and voice outcomes with laser and radiation for the treatment of glottic cancer involving the anterior commissure.
authors.affiliation: Dalhousie University, Division of Otolaryngology - Head and Neck Surgery, Halifax, NS, Canada. smtaylorwashu@yahoo.com.
authors.forename: S Mark
authors.initials: SM
authors.lastname: Taylor
authors.forename: Paul
authors.initials: P
authors.lastname: Kerr
authors.forename: Kevin
authors.initials: K
authors.lastname: Fung
authors.forename: Mankavil K
authors.initials: MK
authors.lastname: Aneeshkumar
authors.forename: Derek
authors.initials: D
authors.lastname: Wilke
authors.forename: Yida
authors.initials: Y
authors.lastname: Jiang
authors.forename: John
authors.initials: J
authors.lastname: Scott
authors.forename: Judith
authors.initials: J
authors.lastname: Phillips
authors.forename: Robert D
authors.initials: RD
authors.lastname: Hart
authors.forename: Jonathan R B
authors.initials: JR
authors.lastname: Trites
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Rigby
mesh_terms: D000368:Aged; D002170:Canada; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D018572:Disease-Free Survival; D005931:Glottis; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D008866:Microsurgery; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D020127:Recovery of Function; D000077195:Squamous Cell Carcinoma of Head and Neck; D016896:Treatment Outcome